Geode Capital Management
CRBP icon

Geode Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Geode Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.76M Buy
187,029
+16,156
+9% +$136K ﹤0.01% 3172
2025
Q4 		$1.39M Buy
170,873
+43,142
+34% +$532K ﹤0.01% 3279
2025
Q3 		$1.62M Sell
127,731
-6,360
-5% -$60.5K ﹤0.01% 3255
2025
Q2 		$926K Sell
134,091
-137,423
-51% -$998K ﹤0.01% 3348
2025
Q1 		$1.44M Buy
271,514
+7,982
+3% +$70.5K ﹤0.01% 3172
2024
Q4 		$3.11M Buy
263,532
+13,773
+6% +$231K ﹤0.01% 2970
2024
Q3 		$5.15M Buy
249,759
+18,702
+8% +$957K ﹤0.01% 2742
2024
Q2 		$10.5M Buy
231,057
+122,249
+112% +$5.14M ﹤0.01% 2296
2024
Q1 		$4.27M Buy
108,808
+70,663
+185% +$1.74M ﹤0.01% 2780
2023
Q4 		$230K Buy
38,145
+964
+3% +$5.17K ﹤0.01% 3889
2023
Q3 		$251K Buy
37,181
+4,316
+13% +$29.9K ﹤0.01% 3888
2023
Q2 		$258K Hold
32,865
– – ﹤0.01% 3925
2023
Q1 		$239K Sell
32,865
-4
-0% -$17 ﹤0.01% 3953
2022
Q4 		$108K Sell
32,869
-78
-0.2% -$300 ﹤0.01% 4369
2022
Q3 		$163K Hold
32,947
– – ﹤0.01% 4319
2022
Q2 		$249K Sell
32,947
-2,612
-7% -$25.2K ﹤0.01% 4136
2022
Q1 		$566K Sell
35,559
-10,904
-23% -$144K ﹤0.01% 3869
2021
Q4 		$858K Buy
46,463
+259
+0.6% +$7.01K ﹤0.01% 3781
2021
Q3 		$1.41M Buy
46,204
+956
+2% +$37.7K ﹤0.01% 3513
2021
Q2 		$2.48M Sell
45,248
-8,336
-16% -$463K ﹤0.01% 3200
2021
Q1 		$3.17M Buy
53,584
+6,958
+15% +$457K ﹤0.01% 3015
2020
Q4 		$1.75M Buy
46,626
+4,493
+11% +$168K ﹤0.01% 3154
2020
Q3 		$2.27M Buy
42,133
+10,654
+34% +$1.93M ﹤0.01% 2811
2020
Q2 		$7.92M Sell
31,479
-1,541
-5% -$311K ﹤0.01% 2071
2020
Q1 		$5.19M Buy
33,020
+7,021
+27% +$1.19M ﹤0.01% 2126
2019
Q4 		$4.26M Buy
25,999
+1,125
+5% +$166K ﹤0.01% 2555
2019
Q3 		$3.63M Buy
24,874
+1,685
+7% +$293K ﹤0.01% 2580
2019
Q2 		$4.82M Buy
23,189
+2,127
+10% +$455K ﹤0.01% 2418
2019
Q1 		$4.39M Buy
21,062
+2,971
+16% +$655K ﹤0.01% 2405
2018
Q4 		$3.17M Buy
18,091
+953
+6% +$190K ﹤0.01% 2501
2018
Q3 		$3.88M Buy
17,138
+702
+4% +$113K ﹤0.01% 2520
2018
Q2 		$2.49M Buy
16,436
+2,642
+19% +$480K ﹤0.01% 2730
2018
Q1 		$2.52M Buy
13,794
+148
+1% +$33.2K ﹤0.01% 2640
2017
Q4 		$2.9M Buy
13,646
+1,267
+10% +$271K ﹤0.01% 2542
2017
Q3 		$2.65M Buy
12,379
+2,950
+31% +$577K ﹤0.01% 2587
2017
Q2 		$1.78M Buy
9,429
+2,723
+41% +$534K ﹤0.01% 2799
2017
Q1 		$1.66M Buy
6,706
+950
+17% +$233K ﹤0.01% 2762
2016
Q4 		$1.46M Buy
5,756
+16
+0.3% +$3.67K ﹤0.01% 2808
2016
Q3 		$1.17M Buy
5,740
+954
+20% +$119K ﹤0.01% 2857
2016
Q2 		$429K Buy
4,786
+1,745
+57% +$137K ﹤0.01% 3280
2016
Q1 		$165 Hold
3,041
– – ﹤0.01% 3688
2015
Q4 		$150K Hold
3,041
– – ﹤0.01% 3779
2015
Q3 		$143K Buy
+3,041
New +$202K ﹤0.01% 3790

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management's CRBP Position: Q1 2026 in Review

Geode Capital Management increased its Corbus Pharmaceuticals (CRBP) stake by 9.5% in Q1 2026, buying an estimated $136K and bringing the position to 187,029 shares worth $1.76M. The position accounts for ﹤0.01% of the portfolio, ranked #3172.

Geode Capital Management first reported a position in CRBP in Q3 2015 and has held it in 43 quarters since. The position peaked at $10.5M in Q2 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • Geode Capital Management held 187,029 shares of Corbus Pharmaceuticals worth $1.76M as of Q1 2026.
  • Geode Capital Management bought 16,156 Corbus Pharmaceuticals shares in Q1 2026, an estimated $136K.
  • Corbus Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3172 holding.
  • Geode Capital Management first reported a position in Corbus Pharmaceuticals in Q3 2015 and has held it in 43 quarters since.
  • Geode Capital Management's Corbus Pharmaceuticals position peaked at $10.5M in Q2 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.